ADARB1 Antibody

Size : 100 µL Clone Number: Aliases: tibody; ADARB1 antibody; 1700057H01Rik antibody; ADAR2 antibody; ADAR2a antibody; ADAR2a L1 antibody; ADAR2a L2 antibody; ADAR2a L3 antibody; ADAR2b antibody; ADAR2c antibody; ADAR2d antibody; ADAR2g antibody; Adarb1 antibody; Adenosine deaminase; RNA specific; 2 antibody; Adenosine deaminase; RNA specific; B1 (homolog of rat RED1) antibody; Adenosine deaminase; RNA specific; B1 (RED1 homolog rat) antibody; Adenosine deaminase; RNA specific; B1 antibody; AW124433 antibody; AW558573 antibody; BB220382 antibody; D10Bwg0447e antibody; Double stranded RNA specific editase 1 antibody; Double-stranded RNA-specific editase 1 antibody; DRABA2 antibody; DRADA2 antibody; dsRNA adenosine deaminase antibody; EC 3.5.-.- antibody; Human dsRNA adenosine deaminase DRADA2 antibody; Human dsRNA adenosine deaminase DRADA2b; EC 3.5 antibody; OTTHUMP00000115341 antibody; OTTHUMP00000115342 antibody; RED 1 antibody; RED1_HUMAN antibody; RNA editase antibody; RNA editase 1 antibody; RNA editing deaminase 1 antibody; RNA editing enzyme 1 antibody; RNA editing enzyme 1; rat; homolog of antibody; RNA specific adenosine deaminase B1 antibody; RNA-editing deaminase 1 antibody; RNA-editing enzyme 1 antibody Product Type: Polyclonal Antibody Immunogen Species: Homo sapiens (Human) UniProt ID: P78563 Immunogen: Synthesized peptide derived from internal of Human ADARB1. Host: Rabbit Reactivity: Human, Mouse, Rat Tested Applications: ELISA, WB; WB: 1: 500-1: 3000 Background: Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing. This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins; pre-mRNA splicing by altering splice site recognition sequences; RNA stability by changing sequences involved in nuclease recognition; genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication; and RNA structure-dependent activities such as microRNA production or targeting or protein-RNA interactions. Can edit both viral and cellular RNAs and can edit RNAs at multiple sites (hyper-editing) or at specific sites (site-specific editing). Its cellular RNA substrates include: bladder cancer-associated protein (BLCAP), neurotransmitter receptors for glutamate (GRIA2 and GRIK2) and serotonin (HTR2C), GABA receptor (GABRA3) and potassium voltage-gated channel (KCNA1). Site-specific RNA editing of transcripts encoding these proteins results in amino acid substitutions which consequently alter their functional activities. Edits GRIA2 at both the Q/R and R/G sites efficiently but converts the adenosine in hotspot1 much less efficiently. Can exert a proviral effect towards human immunodeficiency virus type 1 (HIV-1) and enhances its replication via both an editing-dependent and editing-independent mechanism. The former involves editing of adenosines in the 5'UTR while the latter occurs via suppression of EIF2AK2/PKR activation and function. Can inhibit cell proliferation and migration and can stimulate exocytosis. Mittaz L., Genomics 41: 210-217(1997). Lai F., Mol. Cell. Biol. 17: 2413-2424(1997). Villard L., Somat. Cell Mol. Genet. 23: 135-145(1997). Clonality: Polyclonal Isotype: IgG Purification Method: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. Conjugate: Non-conjugated Buffer: Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Form: liquid Stroage: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze. Target Names: ADARB1 Research Areas: Epigenetics and Nuclear Signaling